Eisai discovered perampanel (E2007) is a AMPA receptor antagonist indicated as a treatment for partial-onset seizures linked with epilepsy.
The company’s submission of the application was supported by the results from three Phase III double-blind, dose-escalation, randomized, place-controlled studies, 306, 305 and 304, which involved around 1,480 patients in the trials.
Each of the studies demonstrated consistent results in the efficacy and tolerability of perampanel given as therapy in patients with refractory partial seizures.